Prostate Cancer P D:MRI-US融合前列腺活检学习曲线鉴定分析

2019-03-18 AlexYang MedSci原创

MRI-US融合前列腺活检在诊断前列腺癌中已经成为一种常见的步骤。考虑到融合活检的学习曲线,仍旧缺乏相关信息。最近,有研究人员研究了在该步骤中能够准确和有效进行时需要的经验量。研究人员前瞻性的搜集了MRI-US融合活检的患者数据,这些融合活检在2014年4月到2017年8月之间进行。研究人员利用2个参数来定义学习曲线,即效率和准确度。之后,他们利用图形和数学的方法来确定学习曲线。研究人员为完成了7

MRI-US融合前列腺活检在诊断前列腺癌中已经成为一种常见的步骤。考虑到融合活检的学习曲线,仍旧缺乏相关信息。最近,有研究人员研究了在该步骤中能够准确和有效进行时需要的经验量。

研究人员前瞻性的搜集了MRI-US融合活检的患者数据,这些融合活检在2014年4月到2017年8月之间进行。研究人员利用2个参数来定义学习曲线,即效率和准确度。之后,他们利用图形和数学的方法来确定学习曲线。研究人员为完成了779份融合活检分析(523次经直肠,256次经会阴)。患者的平均年龄为66岁(IQR61-70),平均PSA6.95ng/ml(IQR4.2-10.6)。前列腺癌的诊断数量为385(49%)。过程测量的手术时间从第一次经直肠融合活检的45分钟到第109次的15分钟,之后保持稳定(p<0.0001)。在经会阴手术中,时间从第一次的55分钟到第124次的18分钟(p<0.001)。PI-RADS 3病灶的经直肠融合活检检出率结果在104次活检之后从35%增加到了50%。 而在经会阴融合活检中,经历119个案例后检出率从40%增加到了55%。

最后,研究人员指出,他们探究了融合活检的学习曲线,并阐释了经直肠融合活检和经会阴融合活检的精通分别需要经历的案例数量为110和125。

原始出处:

Daniel Halstuch, Jack Baniel, David Lifshitz et al. Characterizing the learning curve of MRI-US fusion prostate biopsies. Prostate Cancer P D. 06 Mar 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2046037, encodeId=50d4204603e91, content=<a href='/topic/show?id=e5713251390' target=_blank style='color:#2F92EE;'>#前列腺活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32513, encryptionId=e5713251390, topicName=前列腺活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Mon Apr 15 12:09:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791571, encodeId=78301e915712d, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Jun 15 23:09:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278133, encodeId=ff1e12e813350, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Mar 20 12:09:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364471, encodeId=9f6b13644e1a0, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Mar 20 12:09:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525498, encodeId=8ef8152549804, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Wed Mar 20 12:09:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602134, encodeId=c93a160213411, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Mar 20 12:09:00 CST 2019, time=2019-03-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2046037, encodeId=50d4204603e91, content=<a href='/topic/show?id=e5713251390' target=_blank style='color:#2F92EE;'>#前列腺活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32513, encryptionId=e5713251390, topicName=前列腺活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Mon Apr 15 12:09:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791571, encodeId=78301e915712d, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Jun 15 23:09:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278133, encodeId=ff1e12e813350, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Mar 20 12:09:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364471, encodeId=9f6b13644e1a0, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Mar 20 12:09:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525498, encodeId=8ef8152549804, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Wed Mar 20 12:09:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602134, encodeId=c93a160213411, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Mar 20 12:09:00 CST 2019, time=2019-03-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2046037, encodeId=50d4204603e91, content=<a href='/topic/show?id=e5713251390' target=_blank style='color:#2F92EE;'>#前列腺活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32513, encryptionId=e5713251390, topicName=前列腺活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Mon Apr 15 12:09:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791571, encodeId=78301e915712d, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Jun 15 23:09:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278133, encodeId=ff1e12e813350, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Mar 20 12:09:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364471, encodeId=9f6b13644e1a0, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Mar 20 12:09:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525498, encodeId=8ef8152549804, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Wed Mar 20 12:09:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602134, encodeId=c93a160213411, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Mar 20 12:09:00 CST 2019, time=2019-03-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2046037, encodeId=50d4204603e91, content=<a href='/topic/show?id=e5713251390' target=_blank style='color:#2F92EE;'>#前列腺活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32513, encryptionId=e5713251390, topicName=前列腺活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Mon Apr 15 12:09:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791571, encodeId=78301e915712d, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Jun 15 23:09:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278133, encodeId=ff1e12e813350, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Mar 20 12:09:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364471, encodeId=9f6b13644e1a0, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Mar 20 12:09:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525498, encodeId=8ef8152549804, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Wed Mar 20 12:09:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602134, encodeId=c93a160213411, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Mar 20 12:09:00 CST 2019, time=2019-03-20, status=1, ipAttribution=)]
    2019-03-20 lsndxfj
  5. [GetPortalCommentsPageByObjectIdResponse(id=2046037, encodeId=50d4204603e91, content=<a href='/topic/show?id=e5713251390' target=_blank style='color:#2F92EE;'>#前列腺活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32513, encryptionId=e5713251390, topicName=前列腺活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Mon Apr 15 12:09:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791571, encodeId=78301e915712d, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Jun 15 23:09:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278133, encodeId=ff1e12e813350, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Mar 20 12:09:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364471, encodeId=9f6b13644e1a0, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Mar 20 12:09:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525498, encodeId=8ef8152549804, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Wed Mar 20 12:09:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602134, encodeId=c93a160213411, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Mar 20 12:09:00 CST 2019, time=2019-03-20, status=1, ipAttribution=)]
    2019-03-20 licz0427
  6. [GetPortalCommentsPageByObjectIdResponse(id=2046037, encodeId=50d4204603e91, content=<a href='/topic/show?id=e5713251390' target=_blank style='color:#2F92EE;'>#前列腺活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32513, encryptionId=e5713251390, topicName=前列腺活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Mon Apr 15 12:09:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791571, encodeId=78301e915712d, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Jun 15 23:09:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278133, encodeId=ff1e12e813350, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Mar 20 12:09:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364471, encodeId=9f6b13644e1a0, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Mar 20 12:09:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525498, encodeId=8ef8152549804, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Wed Mar 20 12:09:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602134, encodeId=c93a160213411, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Mar 20 12:09:00 CST 2019, time=2019-03-20, status=1, ipAttribution=)]
    2019-03-20 sunylz

相关资讯

Ann Intern Med:低剂量阿司匹林与前列腺癌诊断后死亡率的关系

由此可见,该研究不支持诊断后低剂量阿司匹林对前列腺癌死亡率的总体影响。然而,延长暴露的结果表明,使用低剂量阿司匹林可能与癌症诊断5年后的前列腺癌死亡率呈负相关。

Sci Rep:p300/CBP相关的因子能够促进δ-连环蛋白的自噬降解和减少前列腺癌的致瘤性

δ-连环蛋白与β-连环蛋白具有共同的结合分子。因为乙酰化和去乙酰化能够调控β-连环蛋白的稳定性,最近,研究人员探寻了组蛋白乙酰转移酶(HATs)或者组蛋白去乙酰化酶(HDACs)在影响δ-连环蛋白乙酰化状态和蛋白水平方面的情况。研究人员发现,p300/CBP相关的因子(PCAF)能够直接结合乙酰化δ-连环蛋白,然而一些I类和II类HDACs能够恢复上述影响。与β-连环蛋白不同,δ-连环蛋白能够通过

Oncogene:MicroRNA-1205与去势难治性前列腺癌风险有关

染色体8q24.21位点包含了原癌基因c-MYC、长非编码RNA PVT1和microRNAs(miRs),是人类前列腺癌中最常见的扩增区域。遗传变异与该位点的c-MYC和长非编码RNA PVT1长期互作能够导致前列腺癌的遗传风险。在该位点包含6个miRs(miR-1204, -1205, -1206, -1207-3p, -1207-5p和-1208),但是他们的功能仍旧未知。最近,有研究人员利

Oncogenesis:二氢青蒿素能够通过JARID2/miR-7/miR-34a依赖的Axl下调来抑制前列腺癌

Axl的表达在一些癌症类型中不受调控,并且能够预测不良总患者生存,且与药物治疗抗性的产生有关。最近,有研究人员评估了Axl天然化合物抑制剂库,鉴定了二氢青蒿素(有效成分为抗疟疾药物青蒿素)可以作为前列腺癌中Axl的抑制剂。研究发现,二氢青蒿素能够阻断Axl的表达从而导致细胞凋亡,减少前列腺癌细胞的细胞增殖、迁移和肿瘤发生。多烯紫杉醇是转移性前列腺癌的标准治疗药物,能够增加人类异种种植小鼠模型的总生

Prostate Cancer P D:MEK-ERK信号是转移去势抵抗性前列腺癌的治疗靶标

转移去势抵抗性前列腺癌(mCRPC)目前难以治愈,以雄激素受体信号为靶标的药物治疗后的恶化也难以避免。因此,除了激素治疗手段外,开发更多有效的治疗方法非常迫切。最近,有研究人员鉴定了已经存在药物和改善过的药物对mCRPC中激活的激酶作为治疗靶标的可能性,目的在于鉴定候选药物从而实现快速将其进入mCRPC概念验证第二阶段试验。研究包括了101名患有mCRPC的患者。研究人员将这101名mCRPC患者

Nucleic Acids Res:揭示长链非编码RNA PCAT1促进去势抵抗性前列腺癌进展的新机制

近期,天津医科大学第二医院牛远杰教授、尚芝群副教授课题组最新报道了长链非编码RNA PCAT1通过调控PHLPP/FKBP51/IKKα蛋白复合体,同时增强AKT和NF-κB两条信号通路,促进去势抵抗性前列腺癌进展中的作用机制。相关研究成果于2019年2月在线发表在权威期刊《Nucleic Acids Res》,题目为“LncRNA PCAT1 activates AKT and NF-κB si